SCANDIVIR WORTH MSEK 100 – SCN SELLS PART OF SHAREHOLDING FOR MSEK 13.5

(NGM:SCN)

Scandinavian Clinical Nutrition AB (SCN) has sold 13.5 percent of the company’s shares in Scandivir AB for MSEK 13.5, setting the value of Scandivir to MSEK 100. Scandivir works with development of diagnostic tests for the obesity virus AD36, and does research on anti-viral compounds (for example SCN’s patented substance NGNA/N5G) to find treatments for common cold and other virus related diseases.

“The market cap of SCN today is about SEK 130 million. However, the fact that we now have sold only a part of our shareholding in the subsidiary Scandivir for SEK 13.5 million sets the value of Scandivir alone to SEK 100 million. This clearly shows that we have managed to build significant underlying values besides the company’s regular activities, and proves that our strategy, to create new and innovative products through alliances with leading researchers in fields of great commercial interest, has potential to build additional value for SCN in the future”, says Thomas Christensen, CEO of SCN.

Scandivir was established in April, 2008, by SCN and the American obesity researcher Professor Richard L. Atkinson. The company’s portfolio incorporates several promising patents around virus related diseases, of which obesity is one, as well as SCN’s patented anti-viral substance NGNA/N5G. Intensive R&D work is being done by Professor Atkinson’s company Obetech at the University of Virginia, with support from SCN’s network of researchers at Karolinska Institutet in Sweden, aiming for a release of a diagnostic test in 2009, and anti-viral treatments soon after.

“SCN sees great potential in Scandivir and the products that the ongoing R&D work will result in. We are confident that the value of Scandivir will grow, and therefore we intend to keep our majority ownership in the company, so that our shareholders get their share of that increased value”, says Ulf Söderberg, Chairman of the Board of SCN.

For more information, please contact:

Thomas Christensen, CEO, tc@scnutrition.com, +47 922 55 444

Ulf Söderberg, Chairman of the Board, us@scnutrition.com, +46 708 13 22 81

Scandinavian Clinical Nutrition AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se). For more information, please visit www.scnutrition.com.